Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Antiviral fungal metabolites and some insights into their contribution to the current COVID-19 pandemic

Jacqueline Aparecida Takahashi, Bianca Vianna Rodrigues Barbosa, Matheus Thomaz Nogueira Silva Lima, Patrícia Gomes Cardoso, Christiane Contigli, Lúcia Pinheiro Santos Pimenta

Department of Chemistry, Exact Sciences Institute, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, CEP 31270-901 Belo Horizonte, MG, Brazil
Department of Food Science, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, CEP 31270-901 Belo Horizonte, MG, Brazil
Department of Biology, Universidade Federal de Lavras, Av. Dr. Sílvio Menicucci, 1001, CEP 37200-900 Lavras, MG, Brazil
Cell Biology Service, Research and Development Department, Fundação Eusequiel Dias, R. Conde Pereira Carneiro, 80, CEP 30510-010 Belo Horizonte, MG, Brazil

ARTICLE INFO

Keywords:
Fungi secondary metabolites
Antiviral compounds
SARS-CoV-2
Molecular docking
Drug discovery

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, which started in late 2019, drove the scientific community to conduct innovative research to contain the spread of the pandemic and to care for those already affected. Since then, the search for new drugs that are effective against the virus has been strengthened. Featuring a relatively low cost of production under well-defined methods of cultivation, fungi have been providing a diversity of antiviral metabolites with unprecedented chemical structures. In this review, we present viral RNA infections highlighting SARS-CoV-2 morphogenesis and the infectious cycle, the targets of known antiviral drugs, and current developments in this area such as drug repurposing. We also explored the metabolic adaptability of fungi during fermentation to produce metabolites active against RNA viruses, along with their chemical structures, and mechanisms of action. Finally, the state of the art of research on SARS-CoV-2 inhibitors of fungal origin is reported, highlighting the metabolites selected by docking studies.

1. Introduction

The world is facing the rapid spread of a novel virus, designated as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the causative agent of coronavirus disease 2019 (COVID-19). The outbreak, which started in December 2019 in Wuhan, China, quickly emerged as a global threat, urging coordinated efforts of authorities, physicians, and scientists to better understand the spread of the virus, and to find potential therapeutics and prophylactics to minimize the socioeconomic and public health effects of such diseases. SARS-CoV-2 was included among the priority viruses in the 2020 WHO Research & Development Blueprint. 1 In the fight against viruses and diseases, there is a huge demand for strategies to increase people’s adherence to reliable models that can decrease virus transmission. By July 20, 2021, SARS-CoV-2 has infected over 190.6 million people worldwide, with over 4 million deaths, and the number is still growing rapidly. 2

Since complete virus eradication is not possible, the search for vaccines directed to prophylaxis strategies and antiviral drugs to treat affected patients is a worldwide priority. Effective drugs to combat SARS-CoV-2 and cure COVID-19 are still being developed, and vaccines are the first choice to contain the spread of the infection. In July 2021, there were 105 COVID-19 vaccine candidates in clinical trials or already being used (see Table 1 for clinical trials). 3,4 However, only 13 vaccines received rapid temporary regulatory approval to address significant public health issues such as pandemic. The vaccine produced by BioNTech in cooperation with Pfizer (BNT162b2/COMIRNATY – INN Tozinameran) was approved in December 2020 and the others by the beginning of 2021. 3,6

Although vaccination is in progress in almost all countries, with more than 2.9 million vaccine doses administered from the end of 2020 to July 2021, 2 mass immunization will not be achieved so quickly to effectively control the pandemic, since several countries cannot afford the costs and logistics for vaccine distribution, stocking, and preservation. In addition to the inherent challenges of this process, the world faces an additional threat due to new SARS-CoV-2 genetic variants with higher virulence, which in certain cases may present the ability to escape
Table 1
COVID-19 vaccines registered on OMS and/or currently used worldwide.

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|-----------------------------------|
| Type: Inactivated SARS-CoV-2                |                               |                                   |
| CoronaVac (SARS-CoV-2 vaccine) [NCT043552608, NCT04383574, NCT049890113, NCT04456595, NCT04582344, NCT04508075, NCT04756830] | Sinovac Research and Development Co. Ltd. (China) | Albania, Armenia, Azerbaijan, Bangladesh, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Cambodia, China, Chile, Colombia, Dominican Republic, Ecuador, Egypt, Georgia, Hong Kong, Indonesia, Kazakhstan, Laos, Libya, Malaysia, Mexico, Moldova, Nepal, Pakistan, Panama, Paraguay, Philippines, Singapore, South Africa, Thailand, Timor-Leste, Togo, Tunisia, Turkey, Turkmenistan, Ukraine, Uruguay, Zimbabwe, WHO Afghanistan, Algeria, Angola, Argentina, Bahrain, Bangladesh, Barbados, Belarus, Bolivia, Bosnia and Herzegovina, Brazil, Brunei, Cambodia, Cameroon, Chad, China, Congo, Dominican Republic, Egypt, Ethiopia, Equatorial Guinea, Gabon, Georgia, Guyana, Hungary, Indonesia, Iraq, Jordan, Kazakhstan, Kyrgyzstan, Laos, Macau, Maldives, Mauritania, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Niger, North Macedonia, Pakistan, Papua New Guinea, Peru, Philippines, Senegal, Serbia, Seychelles, Sierra Leone, Solomon Islands, Somalia, Sri Lanka, Sudan, Thailand, Turkmenistan, UAE, Vamatu, Uzbekistan, Zambia, Zimbabwe |

| BBIBP-CorV [ChiCTR2000032459, NCT045600881, NCT04863638, ChiCTR2000034780, ChiCTR20000401704] | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products (China) | China |

| Covaxin (BBV152) [NCT0471519, NCT04641481, CTY/2020/11/028976, NCT04918797] | Bharat Biotech + India’s National Institute of Virology | Bahrain, India, Mauritius, Mexico, Myanmar, Nepal, Paraguay, Philippines, Venezuela, Vietnam, Zimbabwe, China |

| WIBP-CorV [ChicCTR2000031809, NCT04885764, ChicCTR2000034780] | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products (China) | Russia |

| Covivac | Chumakov Federal Scientific Center for Research and Development of Immune and Biologics Products (Russia) | Kazakhstan |

| QazVac (QazCovid-in) [NCT04530357, NCT04691908] | Research Institute for Biological Safety Problems (Kazakhstan) | China |

| Unnamed vaccine candidate [NCT04758273, NCT04756323, NCT04852705] | Minhai Biotechnology Co. + Shenzhen Kangtai Biological Products Co. Ltd. (China) | China |

| COViran Barekat [IRCT20201202049567N1, IRCT20201202049567N3] | Shifa Pharmad Industrial Group (Iran) | Iran |

| Abdala (CIGB 66) [IG/CIGB-66/CVD/19/2002, IG/CIGB-66/CVD/19/2103] | Center for Genetic Engineering and Biotechnology (Cuba) | Cuba, Venezuela |

| EpiVacCorona [NCT04527575, NCT04780035] | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (Russia) | Belarus, Russia, Turkmenistan |

| Type: SARS-CoV-2 protein unity |                               |                                   |
|--------------------------------|-------------------------------|                                   |
| Type: Recombinant protein subunit ZF2001 [NCT04445194, NCT04466085, NCT045505351, NCT046465500, NCT04833101] | Anhui Zhifei Longcom Biopharmaceutical (Uzbekistan) + Institute of Microbiology, Chinese Academy of Sciences (China) | China, Uzbekistan |

| Type: Conjugated protein subunit Soberana 02 [RPCE00000340, RPCE00000347] | BioCubaFarm + Finlay Institute of Vaccines (Cuba) | Cuba, Iran |

| Type: Non-replicating recombinant adenovirus vector AstraZeneca + University of Oxford (UK) |                               |                                   |

| AstraZeneca + University of Oxford (UK) |                               |                                   |

(continued on next page)
| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Cabo Verde, Cambodia, Canada, Cambodia, Caribbean, Chile, Colombia, Congo, Costa Rica, Djibouti, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Eswatini, Ethiopia, European Union, Faroe Islands, Fiji, Gambia, Georgia, Ghana, Greenland, Guatemala, Guinea-Bissau, Guyana, Honduras, Hungary (SII), Iceland, India, Indonesia, Iran, Iraq, Ivory Coast, Jordan, Kenya, Kosovo, Kuwait, Lebanon, Lesotho, Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Namibia, Nepal, Nicaragua, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palestine, Panama, Papua New Guinea, Peru, Philippines, Rwanda, Saint Vincent and Grenadines, Samoa, Serbia, Seychelles, Sierra Leone, Somalia, South Korea, South Sudan, Sri Lanka, Sudan, Suriname, Taiwan, Tajikistan, Thailand, Timor Leste, Tonga, Togo, Tuvalu, Uganda, Ukraine, UK, Uzbekistan, Vietnam, WHO (Oxford; SII/2K), Yemen, Zambia |

**Table 1 (continued)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Belarus, Bolivia, Brazil, Congo, Djibouti, Ecuador, Egypt, Gabon, Ghana, Guatemala, Guinea, Guyana, Honduras, Hungary, India, Iran, Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Laos, Lebanon, Maldives, Mali, Mexico, Moldova, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nicaragua, North Macedonia, Pakistan, Palestine, Panama, Paraguay, Republika Srpska, Russia (Sputnik Light), Saint Vincent and the Grenadines, San Marino, Serbia, Slovakia, Sri Lanka, Syria, Tunisia, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela, Zimbabwe |

**Type:** Non-replicating recombinant adenovirus vector (rAd26)

**Sputnik V (Gam-COVID-Vac)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Albania, Algeria, Angola, Antigua and Barbuda, Armenia, Azerbaijan, Bahrain, Bangladesh, Gamaleya Research Institute + Health Ministry of the Russian Federation + Acellena Contract Drug Research and Development (Russia) |

**Type:** Non-replicating recombinant adenovirus vector (rAd26 and rAd5)

**Sputnik V (Gam-COVID-Vac)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Arabian, Bangladesh, Botswana, Brazil, Canada, Chile, Colombia, Denmark, EU, Faroe Islands, Greenland, Iceland, India, Kuwait, Liechtenstein, Malaysia, Maldives, Mexico, Moldova, New Zealand, Nigeria, Norway, Philippines, Saint Vincent and the Grenadines, Somalia, Switzerland, Turkey, United Kingdom, United States of America, Uzbekistan, Venezuela, World Health Organization (WHO; Oxford; SII/2K), Yemen, Zambia |

**Type:** Non-replicating recombinant adenovirus vector (Ad5)

**Convidicea (PakVac, Ad5-nCoV)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Argentina, Chile, China, Ecuador, Hungary, Malaysia, Mexico, Moldova, Pakistan |

**Type:** Non-replicating recombinant viral vector

**COVID-19 Vaccine Janssen (UNJ-78436735; Ad26.COV2.S)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Andorra, Australia, Bahrain, Bangladesh, Botswana, Brazil, Canada, Chile, Colombia, Denmark, EU, Faroe Islands, Greenland, Iceland, India, Kuwait, Liechtenstein, Malaysia, Maldives, Mexico, Moldova, New Zealand, Nigeria, Norway, Philippines, Saint Vincent and the Grenadines, Somalia, Switzerland, Turkey, United Kingdom, United States of America, Uzbekistan, Venezuela, World Health Organization (WHO; Oxford; SII/2K), Yemen, Zambia |

**Type:** Non-replicating recombinant adenovirus vector (rAd26)

**Sputnik Light**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Angela, Bahrain, Brazil, Congo, Djibouti, Ecuador, Egypt, Gabon, Ghana, Guatemala, Guinea, Guyana, Honduras, Hungary, India, Iran, Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Laos, Lebanon, Maldives, Mali, Mexico, Moldova, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nicaragua, North Macedonia, Pakistan, Palestine, Panama, Paraguay, Republika Srpska, Russia (Sputnik Light), Saint Vincent and the Grenadines, San Marino, Serbia, Slovakia, Sri Lanka, Syria, Tunisia, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela, Zimbabwe |

**Type:** Non-replicating recombinant adenovirus vector (Ad5)

**Convidicea (PakVac, Ad5-nCoV)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Argentina, Chile, China, Ecuador, Hungary, Malaysia, Mexico, Moldova, Pakistan |

**Type:** Non-replicating recombinant viral vector

**COVID-19 Vaccine Janssen (UNJ-78436735; Ad26.COV2.S)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Andorra, Australia, Bahrain, Bangladesh, Botswana, Brazil, Canada, Chile, Colombia, Denmark, EU, Faroe Islands, Greenland, Iceland, India, Kuwait, Liechtenstein, Malaysia, Maldives, Mexico, Moldova, New Zealand, Nigeria, Norway, Philippines, Saint Vincent and the Grenadines, Somalia, Switzerland, Turkey, United Kingdom, United States of America, Uzbekistan, Venezuela, World Health Organization (WHO; Oxford; SII/2K), Yemen, Zambia |

**Type:** Non-replicating recombinant adenovirus vector (rAd26 and rAd5)

**Sputnik V (Gam-COVID-Vac)**

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|---------------------------------------------|-------------------------------|----------------------------------|
| Albania, Algeria, Angola, Antigua and Barbuda, Armenia, Azerbaijan, Bahrain, Bangladesh, Bulgaria, Canada, Colombia, Costa Rica, Djibouti, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Eswatini, Ethiopia, European Union, Faroe Islands, Fiji, Gambia, Georgia, Ghana, Greenland, Guatemala, Guinea-Bissau, Guyana, Honduras, Hungary (SII), Iceland, India, Indonesia, Iran, Iraq, Ivory Coast, Jordan, Kenya, Kosovo, Kuwait, Lebanon, Lesotho, Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Namibia, Nepal, Nicaragua, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palestine, Panama, Papua New Guinea, Peru, Philippines, Rwanda, Saint Vincent and the Grenadines, Samoa, Serbia, Seychelles, Sierra Leone, Somalia, South Korea, South Sudan, Sri Lanka, Sudan, Suriname, Taiwan, Tajikistan, Thailand, Timor Leste, Tonga, Togo, Tuvalu, Uganda, Ukraine, UK, Uzbekistan, Vietnam, WHO (Oxford; SII/2K), Yemen, Zambia |
Table 1 (continued)

| Published name [Clinical trials registered] | Developer (Country of origin) | Countries of authorization/approval |
|-------------------------------------------|------------------------------|-----------------------------------|
| mRNA based                               | Pfizer/BioNTech + Fosun Pharma (multinacional) | Albania, Andorra, Argentina, Aruba, Australia, Bahrain, Bangladesh, Bosnia and Herzegovina, Brazil, Brunei, Canada, Caribbean, Chile, Colombia, Costa Rica, Ecuador, European Union, Faroe Islands, Greenland, Hong Kong, Iceland, India, Iraq, Israel, Japan, Jordan, Kuwait, Lebanon, Liechtenstein, Macao, Malaysia, Maldives, Mexico, Moldova, Monaco, Mongolia, New Zealand, North Macedonia, Norway, Oman, Palestine, Pakistan, Panama, Peru, Philippines, Qatar, Rwanda, Saint Vincent and the Grenadines, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Sri Lanka, Suriname, Switzerland, Thailand, Tunisia, Turkey, Ukraine, UAE, UK, US (16 and older), Vatican City, Vietnam, WHO Andorra, Australia, Bangladesh, Brazil, Botswana, Canada, Colombia, European Union, Faroe Islands, Greenland, Guatemala, Honduras, Iceland, India, Indonesia, Israel, Japan, Liechtenstein, Maldives, Moldova, Mongolia, Norway, Palestine, Philippines, Qatar, Saint Vincent and the Grenadines, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Kingdom, UAE, United States, Vietnam, WHO |

Type: mRNA based

Continuous (BNT162b2) [NCT04523571,2020–001038-36, NCT04588480, NCT04649921, NCT04754594, NCT04816643, NCT04368728, NCT04761822, NCT04760132, NCT04844489]

From the vaccine-driven immune response. Therefore, current measures to decrease pandemic spread, avoid the insurgence of new variants, and reduce the number of deaths still include social distancing and other behavioral changes, as well as the search for effective drugs for the treatment of infected individuals to ensure patient recovery.

In addition, other viral threats for humankind that afflict restricted groups of individuals or are endemic in specific world regions have been re-emerging, which is also very concerning because of high lethality, severe side effects, high cost of medicines, and absence of effective vaccines. A relevant issue in the re-emergence of viral threats is the intense aerial transportation, migration, and inadequate hygienic-sanitary conditions that contribute to virus dissemination. Hepatitis virus (HV) types A (HAV), B (HBV), C (HCV), D, and E are good examples of major public health concerns, and immediate actions are necessary to achieve the World Health Organization’s goal of eliminating the disease as a public health threat by 2030. Acquired Immune Deficiency Syndrome (AIDS) epidemic caused by Human Immunodeficiency Virus (HIV) has become a major concern in the last 40 years, but, in this case, antiretroviral therapy helped to decrease the number of deaths related to HIV. Outbreaks of other emerging or reemerging viruses such as Dengue virus (DENV), Severe Acute Respiratory Syndrome (SARS) virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Influenza A virus (IAV) have been reported. Fig. 1 presents data on some viruses of worldwide concern.

The reemergence of viral diseases is associated with virus genetic flexibility, especially in fast-mutating RNA viruses, giving them the ability to adapt to new hosts and environments, leading to different epidemiological behaviors at local and global levels. These events allied to their anthropogenic causes, together with the underlying processes of virus mutation and adaptation offer good epidemiological models that could help to predict future pandemic reemergence.

In this review, we discuss some antiviral drugs currently available, the activity and structural features of selected fungal metabolites effective against RNA viruses, and the structures of some interesting antiviral fungal metabolites. Some parallels with demands related to COVID-19 medications are also shown. We hope to shed some light on the huge number of fungal metabolites active against emerging and reemerging viruses, especially to pave the way to conquer COVID-19.

2. An overview of fungal metabolites as drug leads

Among the initiatives to control the spread of viral diseases and the severity of their effects, the development of new antivirals is critical. In this scenario, drug repurposing has been a useful strategy, since toxicity and severe side effects, high cost of medicines, and absence of effective vaccines. A relevant issue in the re-emergence of viral threats is the intense aerial transportation, migration, and inadequate hygienic-sanitary conditions that contribute to virus dissemination. Hepatitis virus (HV) types A (HAV), B (HBV), C (HCV), D, and E are good examples of major public health concerns, and immediate actions are necessary to achieve the World Health Organization’s goal of eliminating the disease as a public health threat by 2030. Acquired Immune Deficiency Syndrome (AIDS) epidemic caused by Human Immunodeficiency Virus (HIV) has become a major concern in the last 40 years, but, in this case, antiretroviral therapy helped to decrease the number of deaths related to HIV. Outbreaks of other emerging or reemerging viruses such as Dengue virus (DENV), Severe Acute Respiratory Syndrome (SARS) virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Influenza A virus (IAV) have been reported. Fig. 1 presents data on some viruses of worldwide concern.

The reemergence of viral diseases is associated with virus genetic flexibility, especially in fast-mutating RNA viruses, giving them the ability to adapt to new hosts and environments, leading to different epidemiological behaviors at local and global levels. These events allied to their anthropogenic causes, together with the underlying processes of virus mutation and adaptation offer good epidemiological models that could help to predict future pandemic reemergence.

In this review, we discuss some antiviral drugs currently available, the activity and structural features of selected fungal metabolites effective against RNA viruses, and the structures of some interesting antiviral fungal metabolites. Some parallels with demands related to COVID-19 medications are also shown. We hope to shed some light on the huge number of fungal metabolites active against emerging and reemerging viruses, especially to pave the way to conquer COVID-19.

2. An overview of fungal metabolites as drug leads

Among the initiatives to control the spread of viral diseases and the severity of their effects, the development of new antivirals is critical. In this scenario, drug repurposing has been a useful strategy, since toxicity and severe side effects, high cost of medicines, and absence of effective vaccines. A relevant issue in the re-emergence of viral threats is the intense aerial transportation, migration, and inadequate hygienic-sanitary conditions that contribute to virus dissemination. Hepatitis virus (HV) types A (HAV), B (HBV), C (HCV), D, and E are good examples of major public health concerns, and immediate actions are necessary to achieve the World Health Organization’s goal of eliminating the disease as a public health threat by 2030. Acquired Immune Deficiency Syndrome (AIDS) epidemic caused by Human Immunodeficiency Virus (HIV) has become a major concern in the last 40 years, but, in this case, antiretroviral therapy helped to decrease the number of deaths related to HIV. Outbreaks of other emerging or reemerging viruses such as Dengue virus (DENV), Severe Acute Respiratory Syndrome (SARS) virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Influenza A virus (IAV) have been reported. Fig. 1 presents data on some viruses of worldwide concern.

The reemergence of viral diseases is associated with virus genetic flexibility, especially in fast-mutating RNA viruses, giving them the ability to adapt to new hosts and environments, leading to different epidemiological behaviors at local and global levels. These events allied to their anthropogenic causes, together with the underlying processes of virus mutation and adaptation offer good epidemiological models that could help to predict future pandemic reemergence.

In this review, we discuss some antiviral drugs currently available, the activity and structural features of selected fungal metabolites effective against RNA viruses, and the structures of some interesting antiviral fungal metabolites. Some parallels with demands related to COVID-19 medications are also shown. We hope to shed some light on the huge number of fungal metabolites active against emerging and reemerging viruses, especially to pave the way to conquer COVID-19.
production costs compared to the development of synthetic drugs, and some early related fungal metabolites are worth revisiting. For instance, in the 1960s, statolon, a polysaccharide produced by \textit{Penicillium stolo}-
\textit{niferum}, was shown to induce interferon production by murine immune cells in response to Friend Leukemia Virus infection, without strong outcomes at that time. After further studies, statolon is currently listed in a patent as an active antiviral compound. Another example comprises an early reported group of antiviral macrocyclic trichothecene mycotoxins, such as verrucarin A (1). Although trichothecenes toxicity, verrucarin J (2) is currently being studied as a drug against lung cancer, while verrucarin A (1) has been reported as one of the three top drugs to bind SARS-CoV-2 protease in docking studies. Verrucarin J and A toxicity is related to several structural factors, such as the double bond between C9 and C10, the epoxide ring between C12 and C13, the number of oxygen substituents, and macrocycle ester functions (Fig. 2).

In another example, chetomin (3) (Fig. 3), a diketopiperazine dimer isolated from \textit{Chaetomium cristatum}, demonstrated potential for inhibiting VSV and toxicity associated with the sulfide bridge, present in this class of molecules, were initially limiting factors for the development of chetomin-based drugs. Based on structure-activity relationship (SAR) studies, less toxic simplified related compounds have been developed with the epidithiodiketopiperazine moiety present in the natural compound chaetocin (4), such as PSETP-1 (5). Meanwhile, thioketopiperazine compounds have been designed and elegantly synthesized using a stereoselective approach, leading to promising antitumor compounds with reduced toxicity. Fig. 3 presents the chemical structures of compounds 3, 4, and 5, highlighting the structural features related to antiviral activity (in red) and toxicity (in black and green).

Therefore, even fungal metabolites previously discarded from clinical trials, due to toxicity issues, may still become drug leads using techniques such as structural simplification and synthesis of derivatives, to achieve less toxic semi-synthetic analogs. These examples

**Fig. 1.** Emergence and reemergence of viral diseases worldwide.

**Fig. 2.** Chemical structures of verrucarins A (1) and J (2), trichothecenes with antiviral potential, highlighting structural features related to toxicity.
demonstrate the value of a new insight over the state-of-the-art of research on fungal metabolites with antiviral activity, directed toward the discovery of effective new prescription drugs for individuals infected with SARS-CoV-2.

3. SARS-CoV-2 infection and COVID-19

Aside from the fact that the Coronaviridae family has been known for almost five decades, specific treatments concerning drugs or vaccination are emerging for SARS-CoV-2 in 2021. Possible therapeutic targets for COVID-19 depend on the molecular mechanisms underlying viral replication, genome sequencing, and proteome identification.

The approach "Breaking the Cycle" (the reproductive cycle) of IAV, HIV, HV, and SARS-CoV-2, based in the diversity of viral families and their specific molecular strategies for host-cell infection and particle replication, has raised important research strategies for treating viral diseases, and it is directing COVID-19 treatment.

Viruses are supramolecular complexes of nucleic acids, either DNA or RNA, encapsulated in a protein coat that may contain proteases or polymerases that are necessary for viral replication inside the cell. SARS-CoV-2 particles (Fig. 4) are protected by a lipid envelope (E), where several proteins with structural and virulence importance [membrane proteins (M), spike proteins (S), and hemagglutinin esterase] are anchored. Viruses can infect organisms of a broad taxa spectrum, with different tropisms. Viral-host specificity is determined by surface proteins (e.g., spike proteins and host receptors) that trigger the adsorption (virus-host interaction) process. In general, host-cell infection occurs via cell fusion between the host-cell plasma membrane and the viral particle or via receptor-mediated endocytosis with particle internalization (endosome). Untied endosomes allow for the release of viral particles inside the cell. Retroviruses replicate through the mediation of complementary DNA (cDNA), copied from the viral RNA genome by reverse transcriptase, and integrated into the chromosomal DNA of the host cells. (--) RNA strands are synthesized by the host, using the viral RNA code integrated into the cell genome, which serve as a template for the synthesis of complementary (+=) RNA strands. The latter are packaged into new virus particles. Viral morphogenesis occurs after the synthesis of proteins from the virus repertoire, using the molecular machinery of the host cells. This step involves the movement of the cytoskeleton for cell remodeling, and impairment of physiological functions of the infected cell.

Considering the extensive differences between virus species reproduction cycles (e.g., enveloped versus non-enveloped virus, DNA versus double-RNA genome), the infectious cycle of SARS-CoV-2, an enveloped virus with a positive-sense single-stranded RNA genome, is briefly presented. The SARS-CoV-2 reproduction cycle, from its early stages to virion particle release, is schematically represented in Fig. 5. Viral infection begins with a random collision between a viral particle and a potential host cell. Before entering, either via endosomal or membrane fusion, SARS-CoV-2 spike proteins must interact with angiotensin-converting enzyme 2 (ACE2) cell receptors to invade the cell. S-glycoprotein-ACE2 engagement is dependent on the proteolytic activity of cathepsin L, an endosomal endopeptidase, and transmembrane protease serine 2 (TMPRSS) when cell infection occurs via membrane fusion. S-cleavage into S1/S2 subunits is essential for host cell invasion and genome release (uncoating). ACE2, which is part of the angiotensin vasoconstriction regulatory axis, is abundantly present in lung epithelial cells, and is therefore implicated in the severe patho-respiratory condition of COVID-19.

Once inside the host cell, the viral genome is released. The SARS-
The SARS-CoV-2 genome contains approximately 30,000 nucleotides and encodes for structural (e.g., envelope proteins) and non-structural proteins (e.g., helicases), including a self-RNA replication/transcription complex (RTC). The replicase complex is encoded by a 20 kb gene in the positive-sense single-stranded RNA. In the host-cell cytoplasm, the coronavirus replicase complex gene is translated into two polyproteins, PP1A and PP1AB, which include 16 non-structural proteins. PP1A and PP1AB are edited by SARS-CoV-2 main protease (M\text{pro})\textsuperscript{30}, also known as chymotrypsin-like protease (3CL\text{pro})\textsuperscript{31} and papain-like protease (PL\text{pro})\textsuperscript{32}.\textsuperscript{33} M\text{pro} recognizes eleven cleavage points, while PL\text{pro} has three predicted cleavage sites over the polyproteins.\textsuperscript{34} Genome replication and viral particle assembly are highly dependent on both proteases. The newly synthesized viral protein structural apparatus develops inside the endoplasmic reticulum and the Golgi apparatus, and sends to progeny assembly, together with genome replicates, providing novel virion particles that are released via exocytosis.\textsuperscript{35} Most of them are prompted by plasma membrane depolymerization, which can be completely ruptured or used to form a lipid envelope around the capsid. This process, even if it does not lyse the cell, makes it infeasible. Extensive changes in host cell physiology and morphology are associated with the cytopathic effects resulting from a viral infection, such as cell lysis, apoptosis initiation, host-cell protein synthesis blockade, membrane transport interruption, cytoskeleton disruption, and host-cell intensive metabolic state. Virulence determines the extension of replication and disease transmission in viruses before host cell failure.\textsuperscript{36}

4. The SARS-CoV-2 protease – The main target for antiviral drugs

Because of the importance of viral proteases for the transcription and replication of Coronavirus, this family of proteins has been considered as a potential target in new drug design.\textsuperscript{37} The SARS-CoV-2 M\text{pro} crystal structure, published in March 2020,\textsuperscript{38} details the substrate-binding pocket (Fig. 6) and target amino acid residues for antiviral design. M\text{pro} is a 3-domain (DI, DII, and DIII) autolytic endopeptidase and its

---

Fig. 5. SARS-CoV-2 reproduction cycle. The schematic cycle of enveloped betacoronavirus divided into four main infection phases. (1) Attachment and entry: viral recognition of the ACE2 host-cell receptor proceeds by spike protein cleavage (S1/S2) for cell invasion engagement. (2) Genome uncoating: after cell fusion or endosomal penetration, the viral genome is released in the host-cytoplasm with nucleocapsid untied. (3) RNA replication and protein production: the main phase in the viral invasion is the use of the host-cell apparatus for virion particle reproduction. The RNA genome is replicated for new particle assembly and translated for viral-protein production including autocatalytic proteases (M\text{pro} and PL\text{pro})\textsuperscript{39}, composing an arsenal of 16 non-structural proteins for replicate assemble. (4) Final process: reorganization of the envelope membrane and the newly synthesized proteins and genome for virion particle release via exocytosis. Some compounds that inhibit viral reproduction are indicated.

---

Fig. 6. SARS-CoV-2 Main Protease 3D structure. M\text{pro} functional protein is organized on a homodimer. Each monomer includes three different functional domains (DI, DII, and DIII). The catalytic cleft is between DI and DII with a His41 and C145 catalytic dyad. DIII is involved in homodimer stabilization. A285 residues differ from SARS-CoV M\text{pro} homolog and contribute to protease activity improvement. Reference protein model PDB 6Y2E.
structure and sequence are conserved among identified coronaviruses, exclusively related to the Coronaviridae family. The genome of SARS-CoV-2 has 82% similarity to its closest betacoronavirus, SARS-CoV, and M PRO holds 96% sequence identity. DI and DII hold the chymotrypsin catalytic gorge, including His41 and Cys145 residues, while DIII N-terminal residues promote homodimerization. In contrast to SARS-CoV M PRO, SARS-CoV-2’s M PRO homodimer does not present a hydrophobic interaction between DIII homodimers, due to a substitution of Thr285 and Ile286 residues to alanine and leucine, respectively, enhancing proteolytic activity. At the same time, these SARS-CoV-2 peculiarities create prominent targets in drug design and development, possibly helping COVID-19 combat.

5. Main classes of antiviral drugs and their potential application to SARS-CoV-2 inhibition

From 1963 to 2016, 90 drugs were formally approved for the treatment of human viruses, eleven of which had broad coverage. Eight antiviral drug classes act on viral metabolic pathways: entry inhibitors, nucleoside and non-nucleoside reverse transcriptase, protease, integrase, acyclic nucleoside phosphonate, pyrophosphate, and 5′-substituted 2′-deoxyuridine analogs. Some drugs target more specific proteins in the cells, such as HCV acyclic guanosine analogs, NS5A/NS5B, neuraminidase, and polymerase inhibitors. Other strategies do not directly target viral proteins, such as interferon immune stimulators, oligonucleotide analogs, and antimitotic inhibitors.

The first class of inhibitors blocks the early stages of viral infection.
during the entry phase, inhibiting the binding of glycoproteins of the viral envelope to host protein receptors. For example, a drug named BMS-378806 (Bristol-Myers Squibb), for human oral administration, is active against HIV-resistant strains, and against viruses with both CCR5 and CXCR4 coreceptors. A closely related pyridine-derivative GS3684934/BMS-663068 (Fostemsavir, GlakoSmithKline - GSK) was submitted to FDA approval. Entry/fusion inhibitors, available for HIV treatment, act at different points of virus penetration, such as the aza-bicyclic maraviric (6) (Fig.7) (known as Celsentri in Europe, and Sel-zentry in the EUA, Pfizer Manufacturing), an antagonist of the HIV CCR5 coreceptor. The peptide Enfuvirtide (T20, Fuzeon, Roche Diagnostics) acts by binding to the transmembrane HR1 region of HIV glycoprotein 41 (gp41), preventing the conformational change of gp41, which is required to complete the fusion process. Sertraline (7) (Zolof, Pfizer), a selective serotonin reuptake inhibitor, and bepridil (8) (Vascor, Ortho-McNeil-Janssen Pharmaceuticals), a calcium channel blocker, inhibit Ebola Virus (EBOV) entry.

The second class of antivirals involves inhibitors of viral genome uncoating (inhibitors of viral uncoating). The first drug approved in this class was amantadine (9), followed by rimantadine and derivatives, but the widespread viral resistance prevented their further utilization. A bicyclam named JMV2763 (10) and the natural products hypericin (11) and pseudohypericin act in the uncoating process.

Nucleoside and non-nucleoside reverse transcriptase inhibitors, which interfere with the multiplication of the viral genome, are the third and fourth classes of antiviral drugs. After the virus enters the host cell, it begins to copy itself. Retroviruses need to copy their RNA into DNA, a process called reverse transcription, mediated by a reverse transcriptase enzyme, that can be inhibited by nucleoside-resembling molecules, called nucleosides reverse and non-nucleoside reverse transcriptase inhibitors. The late are remarkably effective antivirals and, currently, there are six drugs approved by the FDA commercially available: nevirapine (12) (Viramune, Boehringer Ingelheim), delavirdine (Rescriptor, Vii Healthcare), efavirenz (13) (Fig. 7) (Stocrin, MerckSharp&Dohme; Sustiva, Bristol-Myers Squibb; Atripla, Gilead Sciences), etravirine (Intelicure, Janssen Pharmaceutical), rilpivirine (Edurant, Janssen Pharmaceutical), and doravirine (Pifeltro, MerckSharp&Dohme).

Integrate inhibitors and protease inhibitors are antiviral drugs that are mainly directed toward enzymes essential for viral replication. Viral integrases allow the insertion of proviral DNA into the host genome, whereas proteases are involved in the editing of the viral protein arsenal. Three integrate inhibitors, ritonavir (14) (Norvir, Abbott Laboratories), lopinavir (15) (Fig. 7) (Kalera, Abbott C4), and saquinavir (16) (Fortovase, Roche) are currently approved to be used alone or in combination with other drugs, in highly active antiretroviral therapy (HAART). These drugs are protease inhibitors effective against MERS-CoV and HIV-1. Viral mutations are associated with resistance to HIV protease drugs, and they have been frequently used with other drugs in HAART to target multiple stages of the virus life cycle. Ritonavir and saquinavir/lopinavir associations are indicated in more than 90 clinical trials for COVID-19 treatment, according to the World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov, maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) (USA) (2021). Seven protease inhibitors have been approved for clinical use. Telaprevir (Incivo, Janssen-Cilag Pharmaceutical) and simeprevir (Olysio, Janssen-Cilag Pharmaceutical), although the most expensive ones, presented the better response rates. Simeprevir showed great potential to inhibit the enzyme SARS-CoV-2 3CL\textsuperscript{pro} in computational screening. Ritonavir (14) and saquinavir (16) presented high binding energies for SARS-CoV-2 M\textsuperscript{pro}.

Mugisha et al. demonstrated that E64D (inhibitor of endosomal protease cathepsin B and L) and aphilomod (endosomal trafficking inhibitor) significantly reduced SARS-CoV-2 RNA in infected cell cultures, while amprenavir (an HIV-specific protease inhibitor) had a minor effect on the virus.

Nucleosides and nucleotides are other targets for the design of antiviral drugs, such as the adenosine analog GS-5734 (Remdesivir (17), Gilead Sciences) (Fig. 7), active against SARS-CoV and MERS-CoV. This monophosphoramidate prodrug inhibits, in vitro and in vivo, the nonstructural protein 12 RNA-dependent RNA polymerase (RdRp), an essential part of the CoV replication-transcription complex. Therefore, RdRp is another potential drug target for SARS-CoV-2, as Remdesivir (17) is capable of interact with SARS-CoV-2 main protease by means of a stable covalent bond. Remdesivir is cited in more than hundred clinical studies for COVID-19 application, on WHO ICTRP and ClinicalTrials.gov platforms (2021).

Protease inhibitors are also the main targets of HIV infection. For instance, ribavirin (18) (Copegos, Roche) targets viral RNA polymerase, and is effective against five viruses: RSV, DENV, CHIKV, HCV, and IAV. Seven HCV NS3/4A protease compounds have been approved for clinical use, and telaprevir (INCIVO, Janssen-Cilag Pharmaceutical) and simprevir (OLYSIO, Janssen-Cilag Pharmaceutical) have been reported to have better response rates, although they are more expensive.

Oseltamivir (19) (Tamiflu, Gilead Sciences), zanamivir (Relenza, GSK), and peramivir (Rapivab, Biocryst Pharmaceuticals) target viral neuraminidases or mRNA synthesis, and in silico studies demonstrated the docking of oseltamivir (19) to SARS-CoV-2 main protease. Ribavirin (18) participates in six ongoing phase 2 or 3 clinical trials, and oseltamivir in seven clinical studies registered on ClinicalTrials.org (2021).

Most of the aforementioned compounds are synthetic prescription drugs studied in a repurposing approach, since the toxicity, side effects, and industrial production are already known. However, the limited structural diversity of synthetic compounds may be a drawback of this process. Considering the success of natural products as new lead drugs, the screening of these metabolites can increase the chances of developing effective antiviral drugs, taking into consideration the remarkable structural diversity of natural compounds, especially those produced by fungi.

6. Diversity and structural complexity of fungal metabolites as models for new antiviral products

Antiviral fungal metabolites bearing complex chemical structures and novel skeletons from mixed biosynthesis, often considered rare compounds, including protease inhibitors, are well documented and can be further explored to develop potential SARS-CoV-2 inhibitors. Whereas the terrestrial environment is the traditional source of fungi, deep-sea has been a rewarding source of biotechnologically promising fungi, such as some meroterpenoids (diterpene/polyketyde hybrids). One of them, brevione F (20), which exhibits a singular α-pyronine pentacyclic basic carbon framework, inhibits HIV-1 in vitro replication in the human leukemia T cell line C8166. Despite the complex chemical structures of metabolites of the brevione class, usually bearing six stereocenters, enantiocontrolled total synthesis of brevione-related derivatives such as brevione C (21) have been reported, broadening the scope of potential antiviral drugs of compounds from this class. The heterocyclic ether present in the skeleton of brevione metabolites is an important bioisoster of peptide bonds in the development of protease inhibitors. The strong hydrogen bonds formed with the oxygen in the O-heterocycle ring enhance the interaction of these metabolites with the enzyme receptors of drug-resistant viral strains. Amprenavir and darunavir are FDA-approved anti-HIV drugs containing O-heterocycles, demonstrating the role of this moiety in the development of antiviral drugs.

Cladosin C (22), a polyketide isolated from Cladosporium sphaerospermum (Ascomycota), sheds light on a novel class of tetramic acids, possibly formed by the action of a rare aminotransferase domain present in the polyketide synthase gene of this fungus. Cladosin C showed in vitro activity against the cytopathic effect of IAV H1N1. Convergent total synthesis of cladosin C, applied to other members of the cladosin family, was reported. Basidiomycota fungi also revealed promising antiviral substances, such as rhodatin (23), a novel spiroproketal pentacyclic
meroterpene, isolated from the pink mushroom *Rhodotus palmatus*, which is highly active against *in vitro* HCV-infected human liver cells.

Endophytic fungi are another niche that has gained much attention because these organisms can acquire characteristics and uniqueness from host plant biosynthesis. Dimeric anthraquinone alterporriol O (24), which features a new C4-C4’ linkage, was isolated from an endophytic strain of *Alternaria* sp., along with two other alterporriol dimers (25 and 26). The dimers and a hydro-anthraquinone monomer (27) demonstrated *in vitro* activity against porcine reproductive and respiratory syndrome virus (PRRSV) replication in CRL 11,171 cells. Chermesinone B (28), an azaphilone recovered from *Nigrospora* sp., was active against IAV H1N1 in cytopathic inhibition assays. An endophytic strain of *Phoma* sp. (YE3135) produced phomanolide (29), a new rare 14-nordrimane-type sesquiterpenoid, which was able to inhibit the *in vitro* cytopathic effect of IAV. In *in vitro* antiviral activity against HIV-1 was reported for phomopsones B (30) and C (31), new azaphilones with pyranoquinoid core structures, isolated from *Phomopsis* sp. CGMCC No.5416. Carneic acids F and O (32 and 33), isolated from another

Fig. 8. Chemical structures of fungal metabolites (20–36) reported as antiviral agents.
Examples of fungal metabolites, activity against DENV, HV, H1N1, HIV, and ZIKV, and fermentation conditions.

| Fungus name [Origin] | Bioactive metabolite | Antiviral activity [Virus strain] | Culture medium composition | Fermentation details |
|----------------------|----------------------|----------------------------------|-----------------------------|----------------------|
| Dengue Virus (DENV)  | Scequinadoline A (37) | EC<sub>50</sub> 4.73 µM [DENV 2 strain 16,681] | Sea salt (30 g L<sup>-1</sup>), glucose (20 g L<sup>-1</sup>), peptone (5 g L<sup>-1</sup>), yeast extract, i-Phe and D, i-Trp (2 g L<sup>-1</sup> each) | [pH 7.5, 25 °C, 60 days] |
| Penicillium sp. FKI-7127 [Soil around the root of Angelfica keiskei collected in Kouzu Island, Japan]<sup>70</sup> | Brefeldin A (38) | IC<sub>50</sub> 54.6 ± 0.9 mM | Soluble starch 3%, glycerol 1.0%, soybean meal 2%, dry yeast, KCl, CaCO<sub>3</sub>, KH<sub>2</sub>PO<sub>4</sub>, MgSO<sub>4</sub>7H<sub>2</sub>O, and quercetin dihydrate (0.03–0.3%) | [DENV2 strain 00nt-22A [6 days; other details not informed] |
| Phomopsis sp. SNB-LAP1-7–32 [Leaves of Diospyros caronaria, Saint Elie, French Guiana]<sup>71</sup> | Carneic acid F (32) | IC<sub>50</sub> 11.8 ± 0.9 µM | | PDA [26 °C, 15 days] |
| Phomopsis sp. F31-1 [Marine inner tissue of the soft coral Lobophytum crassum, P. R. China]<sup>72</sup> | Carneic acid O (33) | IC<sub>50</sub> 13.6 ± 1.5 µM | | |
| Hepatitis C Virus (HCV) Scedosporium apiospermum 2014F41-1 [Marine soft coral Lobophytum crasum collected from Haiyan Sanya National Coral Reef, P. R. China]<sup>72</sup> | Scedapin C (39) | EC<sub>50</sub> 110.35 µM [HCV genotypes 2b, J8cc] | Glucose (10 g L<sup>-1</sup>), peptone (5 g L<sup>-1</sup>), yeast extract (2 g L<sup>-1</sup>), i-Phe, i-Trp, n-Met, i-Lys, i-Thr (1–2 g L<sup>-1</sup>), sea salt (22 g L<sup>-1</sup>) | [pH 7.5, 28 °C, 40 days] |
| Influenza Virus (IAV) Apergillus sp. SCSIO XWS02F40 [Sponge Gallypogia sp., collected from the sea area near Xuwen County, China]<sup>73</sup> | Asteltoxin E (41) | EC<sub>50</sub> 3.5 ± 1.3 µM | Rice (200 g), sea salt (2.5 g) 200 mL water | [25 °C, 30 days] |
| Phoma sp. strain YE3135 [roots of Aconitum vilmorinianum]<sup>75</sup> | Phomanolide (29) | IC<sub>50</sub> 2.96 ± 0.64 µg/mL [A/Puerto Rico/8/34] | PDB medium | [28 °C, 11 days, 185 rpm] |
| Nigrospora sp. YE3033 [roots of Aconitum carmichaelii collected in Lijiang County, P. R. China]<sup>76</sup> | 6-O-Demethyl-4-dehydroxylatersanol A (43) | IC<sub>50</sub> 2.59 ± 1.22 µg/mL [A/Puerto Rico/8/34] | PDB medium | [28 ± 1 °C, 7 days, 200 rpm] |
| Aspergillus sydowi SCSIO41301 [sponge Phakellia fucosa, collected from the Xisha Islands, China]<sup>77</sup> | 2-Hydroxy-1-(hydroxymethyl)-8-methoxy-3-methyl-9H-xanthene-9-one (46) | IC<sub>50</sub> 4.70 ± 1.11 µM [Puerto Rico 8/34] | Mannitol and maltose (20 g L<sup>-1</sup> each), glucose and monosodium glutamate (10 g L<sup>-1</sup> each), KH<sub>2</sub>PO<sub>4</sub>(0.5 g L<sup>-1</sup>), MgSO<sub>4</sub>·7H<sub>2</sub>O (0.3 g L<sup>-1</sup>), yeast extract (3 g L<sup>-1</sup>), tap water | [pH 7.5, 28 °C, 35 days, static] |
| Human Immunodeficiency Virus (HIV) Phomopsis sp. CGMCC No.5416 [fresh stems of Achyranthes bidentata collected from Nan Ling County, China]<sup>78</sup> | Phomopsone A (48) | IC<sub>50</sub> 0.5 µM [HIV-1] | Rice (80 g 100 mL<sup>-1</sup> water) | [28 °C, 30 days] |
| Penicillium sp. IMB17-046 [marine sediments collected from a mangrove swamp in Sanya, China]<sup>79</sup> | 3,5-di-hydroxyergosta-8,14,24(28)-tri-en-7-one (49) | IC<sub>50</sub> 3.5 ± 0.8 µM [HIV-1] | Rice (100 g), peptone (0.3 g 100 mL<sup>-1</sup> water | [28 °C, 4 weeks] |

(continued on next page)
Phomopsis species (SNB-LAP1-7–32), exhibited significant inhibition of DENV-2 polymerase. The activity of carneic acid F (32) was attributed to the β-hydroxyl group present in its structure.27

The screening of fungi from niches such as Antarctica is supported by the metabolic differentiation in fungal biosynthesis necessary for survival under drastic climatic conditions. This behavior was observed for the Antarctic species Aspergillus ochraceopetaliformis (SCSIO 05702), which produces ochraceopeenone A (34), a linear tetracyclic α-pyrene merosequiterpenoid with a new skeleton, along with isoasteltoxin (35) and asteltoxin (36). These compounds effectively inhibited the cytotoxic in vitro effect of IAV H1N1 and H3N2 strains.68 The structures of metabolites 20–36 are shown in Fig. 8.

7. Strategies on the search of new antiviral metabolites from fungi

The adaptive ability of fungi to different fermentation protocols, upon alteration of parameters such as carbon and nitrogen sources, availability of macro and micronutrients, pH, fermentation length, and temperature variation, can be exploited in the production of new antiviral metabolites. Rice is frequently reported as a substrate for the production of fungal metabolites 69 (Table 2), although reproducibility in rice-based culture medium should be carefully evaluated, considering commercial variation. The cultivation length can be as short as six days or more than seventy days.71 Table 2 presents the profiles of antiviral activity and fermentative conditions to produce fungal metabolites such as scequinadione A (37) and brefeldin A (38), active against DENV, sceadipin C (39), scequinadoline D (40) active against HVC, asteltoxins E and F (41 and 42), altersolanes (43–45) and xanthenones (46–47) (IAV inhibitors). Metabolites active against HIV (48–50) and Zika Virus (ZIKV) (51–53) are also shown. The structures of the metabolites 37–53 are shown in Fig. 9.

Measurement of medium depletion can determine the fermentation stop-point, an approach used by Narmani et al.72 during the recovery of prenylated p-terphenyl quinine metabolites from Cytospora sp. However, fermentation length does not follow a restrictive unique rule regarding productivity, as exemplified by experiments with Scedosporium apiospermum (40 days; 0.22 g L−1 yield),72 Phoma sp. (11 days; 1.1 g L−1 yield),72 and Simplicillium obvolutum (30 days; about the same yield, 1.09 g L−1).80

In most studies cited herein, metabolite isolation usually started using silica gel vacuum liquid chromatography, followed by a Sephadex LH20 column,27 preparative Reversed Phase (RP)-C18 High-Performance Liquid Chromatography (HPLC),73,75 and RP-18 silica gel.73 Direct loading of aqueous extract on a Sep-Pak plus ODS cartridge may be incorporated in the purification protocol,72 as well as the use of amberlite XAD-16 polymeric resin.79 XAD-16 resin (non-ionic poly styrene-divinylbenzene) is highly stable in both acidic and basic solutions, and selectively retains substances in the column without exhaustion of the column material.71 This process might be used as a cleanup step, before chromatographic separation.

Nevertheless, the purification of fungal metabolites in research laboratories for antiviral screening can become a game of patience. During the development of new drugs, low yields can be overcome using bench-size bioreactors and genetic manipulation.52 Detection of the major compounds present in crude extracts, before the isolation step, is useful to direct the efforts, optimize time-consuming purification processes, and avoid re-isolation of known compounds. Nuclear Magnetic Resonance (NMR)-directed isolation is very effective in targeting specific classes of compounds in crude extracts or fractions. In this approach, the isolation step is monitored by NMR, and only extract/fractions with chemical shifts related to the target compounds are further purified or assayed, as successfully demonstrated during the isolation of allenyl (54–56) and alkynyl truncateoles O (57) and P (50) from Truncatella angustata.75 Metabolome analysis by Liquid Chromatography coupled to High-Resolution Mass Spectrometry (LC-HRMS)69, Liquid Chromatography-Electrospray Ionization-Quadrupole-Time of Flight-Mass Spectrometry (LC–ESI–Q–TOF–MS)73 can quickly map secondary metabolites from molecular ions, with high accuracy and isotopic ratio measurements. Ultra-Performance Liquid Chromatography (UPLC) may speed the process, coupled with HRMS, providing both quantitative and structural information, achieving pg/mL−1 sensitivity.53 Nothias et al.85 identified a “bioactive molecular networking,” applying Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS) to fractions obtained from bioactive extracts.

Biosynthesis-directed fermentation is an alternative approach for obtaining secondary metabolites. Huang et al.74 supplementation of amino acids (l-tryptophan, l-phenylalanine, l-threonine, and D, l-methionine) to the culture medium led to the production of three formamides and 18 quinazoline-containing indole alkaloids. A metabolome analysis by Liquid Chromatography-Electrospray Ionization-Quadrupole-Time of Flight-Mass Spectrometry (LC–ESI–Q–TOF–MS)73 can quickly map secondary metabolites from molecular ions, with high accuracy and isotopic ratio measurements. Ultra-Performance Liquid Chromatography (UPLC) may speed the process, coupled with HRMS, providing both quantitative and structural information, achieving pg/mL−1 sensitivity.53 Nothias et al.85 identified a “bioactive molecular networking,” applying Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS) to fractions obtained from bioactive extracts.

Table 2 (continued)

| Fungus name [Origin] | Bioactive metabolite | Antiviral activity [Virus strain] | Culture medium composition [Fermentation details] |
|----------------------|----------------------|----------------------------------|-----------------------------------------------|
| Truncatella angustata XSI-01–43 [Reef-finger sponge Amphimedon sp. collected in Yongxing Island, China] 27 | | | |
| Fusarium sp. 1 [sea star Acelminaster planci, Xisha Islands, China] 77–80 | Fusainoterpenes B (51) | | Rice (80 g 100 mL−1 water [25 °C, 40 days]) |
| Colispora cavincola 74 | 1,2-bis(1H-indol-3-yl)ethane-1,2-dione (52) | | GPy liquid medium [28 °C, 40 days] |
| Cavinafungin (53) | | | |
complex biological structures.

The quantity of viral proteins and reduction of viral nucleic acids in infected cells have been measured in assays against non-cytopathic viruses. Polymerases are essential for all viruses and are excellent targets for antiviral therapies; therefore, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) has been the preferred method for monitoring the activity of DNA polymerases (cellular or viral) in the presence of inhibitors, and has become a standard model for screening viral RNA polymerase inhibitors. Quantitative detection can be achieved using a wide variety of sequence-specific probes or non-specific fluorescent dyes that bind to the genetic material. Mugisha et al. proposed a simplified and efficient method to detect viral RNA in cell culture supernatants, to reduce the costs of qRT-PCR used to monitor the response of SARS-CoV-2 to potential antivirals.

Additionally, computer-aided drug design has been widely utilized in the search for antiviral agents, because it is a reliable, fast, sustainable, and cheap approach compared to wet-lab testing. Tridimensional molecular models of candidate molecules and/or molecular targets can be built and studied in silico under different conditions, and the results are statistically processed. This strategy can be directed to the receptor (structure-based drug design) or ligand (ligand-based drug design) depending on a series of factors and data availability. Many studies have used structure–activity relationship (SAR) tools to identify potentially bioactive metabolites and to plan the synthesis of derivatives bearing antiviral pharmacophoric groups. This approach led to the identification of exocyclic double bond and oxidation on specific groups as key structural features related to the inhibition of HIV-1 cellular infection by eight armochaetoglobins isolated from the symbiotic fungus...
Chaetomium globosum TW1-1. Likewise, the inhibit the cytopathic effect of IAV H1N1 (A/WSN/33 strain) was associated by SAR with specific substituents at the diketopiperazine moiety of rubrumline D (58) and other related metabolites, isolated from marine-derived Eurotium rubrum F33. The positive effect of alkynyl groups in activity enhancement, reported for truncateols O and P (57 and 50) (Fig. 10), metabolites isolated from the fungi species T. angustata, were successfully pointed by SAR studies. The low cytotoxicity of these truncateols compared to the positive control used in the work, efavirenz (13), an antiretroviral drug prescribed for patients with HIV-1, encourages further studies on this class of compounds.

SAR is also important for the synthesis of analogs, as shown in the stereoselective synthesis of reubrolides R and S (59 and 60), where SAR directed the introduction of a β-aryl substituent at a late stage of the synthesis, aiming at the preparation of antiviral compounds. In the synthesis field, click-chemistry and modern fluorescence microscopy techniques together allow site-specific design of new molecules, based on the interaction of host cells and viral factors, and seems very promising in the near future.

Multi-target and in silico screenings are advantageous over single strain-directed assays, as a fungal species can produce metabolites that are active against different viruses. For example, three compounds isolated from a marine-derived species of Penicillium sp. were screened to assess the relative inhibition of three viruses (HIV-1, IAV H1N1 and HCV). One of the compounds, trypilepyrazinol (61) demonstrated in vitro protective effects against HIV-1 and HCV. Trypilepyrazinol is a new polyketide derivative that contains a pyrazine heterocycle, an important pharmacophore found in many bioactive drugs, as part of its structure. The other two compounds, (-)-neocitreoviridin (62) and a new ergostane analog (63) presented a different behavior, being active against IAV H1N1. The different selectivities of metabolites 61, 62, and 63 were only observed because different viruses were included in the experimental protocol. On the other hand, some metabolites present broad antiviral activity, as reported for brefeldin A (38) (Fig. 9), isolated from Penicillium sp. FKI-7127, which selectively inhibited four Filipino patient-derived DENV strains and ZIKV (strain 976) once subjected to a multi-target antiviral assay. The structures of metabolites 54–64 are shown in Fig. 10.

Resistance is a major problem that must be taken into consideration in antiviral screening to develop drugs that are effective also against resistant strains. In this context, the fungal metabolite neoechinulin B (64), produced by E. rubrum F33, was tested against IAV, a virus resistant to commercial drugs such as ribavirin (18). The fungal metabolite neoechinulin B (64) acts at the viral entry stage, binding to the viral hemagglutinin. As the interaction with sialic acid receptors on host cells is avoided, this compound does not promote significant drug resistance in clinical isolates.

Overall, the chemical structures of antiviral drugs 6–19 are diversified enough to selectively target RNA viral proteins according to their respective mechanisms of action. Pharmacophore-based approaches are among the current protocols for repurposing drugs as SARS-CoV-2 inhibitors. Using this approach, compounds bearing indoloquinoline, benzimidazole, indolyl, and carbamate moieties were among the five top drugs with higher docking scores to inhibit viral Mpro. In the same way, antiviral fungal metabolites also feature high chemical diversity, including heterocyclic diazo scequinadoline A (37), macrocycle brefeldin A (38), and anthraquinones (44 and 45). There are some similarities among the structures of the antiviral drugs (Fig. 7) and antiviral fungal metabolites (Figs. 8–11). Fungal metabolites chetomin (3), cladosin C (22), scequinadoline A and D (37 and 40), and trypilepyrazinol (61) present nitrogenated heterocycles in their structures, a moiety commonly found in the structure of antiviral drugs. In addition, the
indole moiety, an important pharmacophore targeted in the research for novel antiviral drugs, 97 is present in the structures of fusaidoterpene B (51), bisindol derivative (52), rubrumline D (58), tryplypyrazol (61), neoechinulin (64), and notoamide I (74). Some pharmacophore groups present in the structure of several of the metabolites herein discussed, such as azaphilone (compounds 28, 30 and 31), α-pyrene (compounds 20, 21, 34–36, 41, 42, 62, and 73) and anthraquinone (25) rings have been suggested as possible inhibitors of SARS-CoV-2, considering the protease inhibition related to compounds with similar structures. 48

All these antiviral metabolites biosynthesized by fungi, with unique molecular structures, are interesting molecules in the search for new antiviral candidates against SARS-CoV-2. In addition, the rational design of inhibitors of influenza virus replication 98 and HIV-1 protease inhibitors, 99 can be applied in the search for drug leads against SARS-CoV-2 100. These are encouraging data in the ongoing search for new antiviral drugs since, despite the importance of vaccines, antiviral medicines are necessary to treat infected patients for symptom relief, reducing the hospitalization period.

Fig. 11. Chemical structures of fungal metabolites 65–83 with potential SARS-CoV-2 antiviral effect.
S protein = SARS-CoV-2 spike protein; Mpro = SARS-CoV-2 main protease, also known as 3CLpro = SARS-CoV-2 chymotrypsin-like protease; PLpro = papain-like protease; 3CLpro = SARS-CoV-2 chymotrypsin-like protease; RdRp = RNA-directed RNA polymerase; nsP15 = non-structural protein 15. ADMET = absorption, distribution, metabolism, excretion, and toxicity; QSAR = quantitative structure-activity relationship; SAR = structure-activity relationship.

8. SARS-CoV-2 inhibitors based in known fungi metabolites

In the worldwide efforts to find an effective treatment for COVID-19, several FDA-approved drugs, from distinct natural sources or synthetically designed, are being evaluated for their interaction with SARS-CoV-2 proteins, using in silico strategies. Most in silico studies, as shown, use molecular docking, which allows the estimation of the activity of a target ligand at the receptor site, based on the most probable chemical interactions between them.\textsuperscript{91,101,102} Docking programs have been improved to add new tools, aiming to increase the reliability of the process and, consequently, the chance of discovering potential drug leads. A combination of docking studies with the molecular dynamic approach, such as the super-computer-based drug discovery pipeline, was reported by Acharya et al.\textsuperscript{103}

Molecular docking has already revealed the high affinity of oseltamivir (19), delavirdine, ritonavir (14), saquinavir (16) and remdesivir (17) for SARS-CoV-2 main protease, achieved by a covalent bond to Cys145 and variable H-bonds. Additional molecular dynamic analysis demonstrated a reduction in Mpro\textsuperscript{67} structural flexibility induced by 14, 16 and 17, indicating a possible impairment of its biological function.\textsuperscript{106} The high affinity of etravirine, lopivirine, and nevirapine (12) for the SARS-CoV-2 protease active site was also revealed by molecular docking studies, and nevirapine (12) presented a higher IC\textsubscript{50} (half-maximal inhibitory concentration) for SARS-CoV-2 than for HIV protein.\textsuperscript{104}

Docking simulations directed to drug repurposing spare time and resources, since prescription drugs have already passed the initial clinical and toxicity trials.\textsuperscript{90,104,106,107}

Likewise, a number of fungal natural compounds have been identified as interesting starting points for the development of COVID-19 therapeutic agents, as indicated by computational studies and preliminary in \textit{vivo} assays.\textsuperscript{100,102,106,113} Based on their similarities to the non-nucleoside reverse transcriptase inhibitor efavirenz (13), considered a repurposing drug candidate for COVID-19 treatment,\textsuperscript{105} the FDA-approved metabolite podophyllotoxin isolated from endophytic fungi,\textsuperscript{114} lovastatin (a well-known fungal metabolite) and its derivative simvastatin were evaluated for their interaction with SARS-CoV-2 proteins, using virtual screening, molecular docking, and density functional theory, with promising results.\textsuperscript{106}

Table 3 reports complementary in silico analysis made to determine the affinity of some molecules deposited in databases and fungal metabolites for the main proteins of SARS-CoV-2, aiming at determining their potential side effects as antiviral drugs. Their corresponding chemical structures are presented in Figs. 9 and 11.

Using molecular docking, dynamics simulations and ADMET analysis to screen a hundred of fungal secondary metabolites, Rao et al.\textsuperscript{115,102} revealed flaviloin (65) and pyranorignin A (66) as drug candidates against SARS-CoV-2, considering their ability to bind and inhibit Mpro, and their drug-likeness ADMET properties, especially low toxicity, when compared with the synthetic compound N3 (PubChem CID 6323191) used as positive control (Table 3, Fig. 11). The same approach was applied in another study, with a larger number of metabolites from different taxa, pointing to three other fungal compounds, jasmonic acid (67) and putaminoxin D (68), as potential inhibitors of Mpro, with favorable ADMET properties.\textsuperscript{108}

Cordycepin (69) is a secondary metabolite produced by \textit{Cordyceps militaris}, with a broad spectrum of biological activities, including antiviral action.\textsuperscript{115} Molecular interaction simulations revealed its high binding affinity to both SARS-CoV-2 Mpro and spike protein binding sites.\textsuperscript{107,109} Moreover, this molecule has a remarkable similarity to adenosine, indicating an additional role in inhibiting the poly(A) polymerase, which is essential for 3′-polyadenylation of viral RNAs like SARS-CoV-2.\textsuperscript{107} Pharmacology network predictions also reinforce the potential role of cordycepin (69) in multiple biological pathways associated with viral infections, signaling it as a repurposing drug candidate for COVID-19 treatment.\textsuperscript{107,109}

Quimque et al.\textsuperscript{110}, using molecular docking and dynamic simulations

---

### Table 3

| Metabolite            | Source                | Mechanism                                      | Methodology                                      |
|-----------------------|-----------------------|------------------------------------------------|------------------------------------------------|
| Flaviloin (65)        | Exploratory library   | Inhibition of M\textsuperscript{pro} (3CLpro, PLpro) | In silico molecular docking analysis, dynamics simulation and ADMET properties |
| Pyranorignin A (66)  | Exploratory library   | Inhibition of M\textsuperscript{pro} (3CLpro, PLpro) | In silico molecular docking analysis, dynamics simulation and ADMET predictions |
| Jasmonic acid (67)   | Stagonospora cirrii   | Inhibition of M\textsuperscript{pro}, drug-like ADMET properties | In silico molecular docking analysis, dynamics simulation and ADMET predictions |
| Putaminoxin B (66)   | Phoma putaminum       |                                                  |                                                  |
| Cordycepin (69)      | Cordyceps militaris   | Binding affinity to S protein and M\textsuperscript{pro}, inhibition of poly (A) polymerase, action in multiple pathways | In silico molecular docking analysis, pharmacology network prediction, SAR |
| Scedapin C (39)      | Exploratory library   | Binding affinity to PL\textsuperscript{pro}, M\textsuperscript{pro}, RdRp, nsP15, and S binding domain | In silico molecular docking analysis, dynamics simulation, and ADMET predictions |
| Isochaetochromin D1 (70) | Exploratory library | Binding affinity to PL\textsuperscript{pro}, M\textsuperscript{pro}, RdRp, nsP15, and S binding domain | In silico molecular docking analysis, dynamics simulation, and ADMET predictions |
| Quinadoline B (71)   | Exploratory library   | Binding affinity to PL\textsuperscript{pro}, M\textsuperscript{pro}, RdRp, nsP15, and S binding domain; high gastrointestinal absorption, poor blood-brain barrier penetrability, drugability, non-toxic, non-carcinogenic, non-mutagenic | In silico molecular docking analysis, pharmacology network prediction, SAR |
| Colossolactone VIII (76) | Ganoderma colusum   | Binding affinity to M\textsuperscript{pro} | In silico molecular docking analysis and AD MET predictions |
| Colossolactone G (77) |                        |                                                  |                                                  |
| Colossolactone E (78) |                        |                                                  |                                                  |
| Ergosterol (79)       | Aeuricularia polyarca, Flammulina velutipes, Lentinula edodes | Inhibition of M\textsuperscript{pro} Non-toxic, non-carcinogenic, non-mutagenic | In silico QSAR, molecular docking analysis and AD MET predictions |
| Emetinol SB (75)     |                        |                                                  |                                                  |
| Colosolactone VIII (76) |                        |                                                  |                                                  |
| Colosolactone G (77) |                        |                                                  |                                                  |
| Colosolactone E (78) |                        |                                                  |                                                  |
| Ergosterol (79),     | Aeuricularia polyarca, Flammulina velutipes, Lentinula edodes | Inhibition of M\textsuperscript{pro} Non-toxic, non-carcinogenic, non-mutagenic | In silico molecular docking analysis and AD MET predictions |
| Heliantriol F (80)   |                        |                                                  |                                                  |
| Velutin (81)         | Aeuricularia polyarca, Flammulina velutipes | Affinity to M\textsuperscript{pro} and viral RNA polymerase, drug-like ADMET properties | In silico molecular docking analysis, AD MET predictions |
| Quercetin (82)       | PubChem database      |                                                  |                                                  |
Indeed, quercetin (70) revealed five multitarget molecules, scedapin C (71), quinodimino B (71), norquinodimino A (72), and 11α-dehydroxyiso-terreulactone A (73), with dynamic stable binding affinities to SARS-CoV-2 proteases PLpro and 3CLpro, RNA-directed RNA polymerase (RdRp), non-structural protein 15 (nsp15), and S protein. These metabolites were then submitted to in silico ADMET predictions, indicating that quinodimino B (71) is the most promising, according to its pharmacokinetic profile, especially oral bioavailability, high drug-likeness, and absence of toxicity.110

Using similar in silico approaches, several other fungal secondary metabolites were indicated as promising drug-like leads against SARS-CoV-2 MPpro. Notoamide I (74) and emindole SB β-mannoside (75) were selected from a panel of 494 marine natural substances, pre-evaluated by a QSAR classification model, and further by molecular docking and ADMET predictions.100 Among the 36 metabolites from edible and medicinal mushrooms, colossolactone VIII (76), colosolactone G (77), colossolactone E (78), ergosterol (79), heliantriol F (80), and velutin (81) were emphasized as good drug candidates as they did not presented relevant toxic, carcinogenic, or mutagenic side effects.112

Quercetin (82) is also a promising candidate for the development of drugs for COVID-19 treatment. According to in silico studies, the compound demonstrated high affinity for the active site of 3CLpro, as well as for the active site and the NiRAN subdomain of SARS-CoV-2 RNA-polymerase, potential targets to viral inhibition.111 Quercetin (82) presents important advantages in drug development, as its pharmacokinetic and ADMET properties are related.110 Literature have pointed out quercetin, as well as ergosterol (79), as anti-inflammatory agents,109,110,118,119,120,121 indicating their possible effect on protecting patients from severe inflammation induced by SARS-CoV-2 infection.83

Indeed, quercetin (82) is the focus of several studies to evaluate its effect on prophylaxis and or treatment for COVID-19, according to WHO ICTRP and ClinicalTrials.gov databases (Fig. 12).

9. Conclusion

Fungi have long been known as sources of molecules with great diversity, and many them exhibit activity against diverse human emerging and reemerging pathogenic viruses. The “arsenal” of candidate molecules produced by fungi, with a broad spectrum of antiviral activities, encourages continuous efforts to explore the potential of this chemical library in drug discovery programs. The lack of effective drug treatment for SARS-CoV and MERS-CoV, as well as the potential of coronaviruses to cause epidemics, emphasizes the need for novel drugs to treat CoV infections associated with immunization programs. The use of technological approaches to diversify fungal metabolic pathways, automated pharmacological testing, computational molecular design and docking have been guiding further in vitro and in vivo studies to find suitable drug leads against viruses. In these multidisciplinary scenarios, fungal metabolites are promising sources of compounds that can interfere with different targets of virus life cycles, as shown in some ongoing studies searching for drugs to fight SARS-CoV-2 infection.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors gratefully acknowledge the financial support from Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG PPM-00255-18), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ Grants 304922/2018-8 and 121994/2019-8), and the Instituto Nacional de Ciência e Tecnologia (INCT BioNat/CNPQ Grant 465637/2014-0), Brazil. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brazil (CAPES) – Finance Code 001.

Authors’ contributions

JAT proposed the review topic. All authors participated in drafting, critically revised, read and approved the final submitted version. BVRB, LPSP and JAT draft and revised the chemical structures. MNSL drew Figs. 4–6.

References

1 WHO - World Health Organization. Prioritizing diseases for research and development in emergency contexts; 2020. https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts. Accessed 3 November 2020.
2 WHO - World Health Organization. WHO Coronavirus (COVID-19) Dashboard; 2021. https://covid19.who.int. Accessed 6 July 2021.
3 WHO - World Health Organization. COVID-19 vaccine tracker and landscape; 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 6 July 2021.
4 Craven J. Covid-19 Vaccine Tracker. Regulatory Affairs Professionals Society; 2021. https://www.raps.org/news-articles/news-articles/2020/3/covid-19-vaccine-tracker. Accessed 6 July 2021.
5 WHO - World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process; 2021. https://extranet.who.int/pwpweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021_v2.pdf. Accessed 6 July 2021.
6 WHO - World Health Organization. Q&A Detail/Coronavirus disease (COVID-19): Vaccines. Is there a vaccine for COVID-19?; 2021. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines. Accessed 6 July 2021.
7 Dholariya S, Parchwani DN, Singh R, Sonagra A, Motiani A, Patel D. Notable and emerging variants of SARS-CoV-2 virus: a quick glance. Indian J Clin Biochem. 2021: 1–8. https://doi.org/10.1007/s12291-021-00991-0.
8 Kannan S, ShRay Syed Ali P, Sheeza A. Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021;25:4405-4412. https://doi.org/10.26715/ermphs_202106261511.
9 WHO - World Health Organization. Hepatitis; 2019. https://www.who.int/health-topics/hepatitis#tab=tab-1. Accessed 6 July 2021.
10 Granich R, Gupta S, Wollmers M, Ruffner M, Williams B. Modeling the HIV epidemic: why the 95–95–95 target and ART effectiveness parameters matter. Int J Virol AIDS. 2018;5:1–9. https://doi.org/10.23937/2469-507X/1510041.
Amaro RE, Baudry J, Chodera J, et al. Ensemble docking in drug discovery. Bioinformatics 2011;27:4271–2278. https://doi.org/10.1093/bioinformatics/btr568.

92 Chen C, Zhu H, Wang J, et al. Armoachaetogenin K R, anti-HIV pyrrole-based cytochalasans from Chantammum globosum TWI-1. Eur J Org Chem. 2015;14: 3806–3809. https://doi.org/10.1002/ejoc.201500239.

93 Chen X, Si L, Liu D, et al. Neocembrin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. Eur J Med Chem. 2015;95:181–185. https://doi.org/10.1016/j.ejmech.2015.02.006.

94 Morimoto TA, Laffer-Larrache B, Boisard A, et al. BCP, a naturally occurring, stereocoregulated and modular synthases of the anti-influenza rubridesides R and S. Tetrahedron Lett. 2016;90, 151307. https://doi.org/10.1016/j.tetlet.2019.151307.

95 Müller TG, Salkin V, Müller B. A spotlight on viruses-application of click chemistry to visualize virus-cell interactions. Molecules. 2019;24:481. https://doi.org/10.3390/240800481.

96 von Itzenstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418–423. https://doi.org/10.1038/363418a0.
117 Xiong Y, Zhu GH, Wang HN, et al. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CLpro from Ginkgo biloba leaves via large-scale screening. *Int J Biol Macromol*. 2020;164:1693–1703. https://doi.org/10.1016/j.ijbiomac.2020.07.235.

118 Liu C, Zhao S, Zhu C, et al. Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. *Fitoterapia*. 2021;152, 104909. https://doi.org/10.1016/j.fitote.2021.104909.

119 Saeedi-Boroujeni A, Mahmoudian-Sani M-R. Anti-inflammatory potential of Quercetin in Covid-19 treatment. *J Inflamm*. 2021;18:3. https://doi.org/10.1186/s12950-021-00268-6.

120 Yang B, Zheng C-Y, Zhang R, Zhao C, Li S, An Y. Quercetin efficiently alleviates TNF-α-stimulated injury by signal transducer and activator of transcription 1 and mitogen-activated protein kinase pathway in H9c2 Cells: a protective role of quercetin in myocarditis. *J Cardiovasc Pharmacol*. 2021;77:570–577. https://doi.org/10.1097/FJC.0000000000001000.